Hepatitis C virus genotype 4 responds better to pegylated interferon with ribavirin than genotype 1 in HIV-infected patients

AIDS

Volumn 26, Issue 13, 2012, Pages 1721-1724

  Mira, José A ^a   Rivero, Antonio ^b,c   De Los Santos Gil, Ignacio ^d   López Cortés, Luis F ^e   Girón González, José A ^f   Márquez, Manuel ^g   Merino, Dolores ^h   Del Mar Viloria, María ^a   Téllez, Francisco ⁱ   Ríos Villegas, María J ^j   Omar, Mohamed ^k   Rivero Juárez, Antonio ^b,c   MacÍas, Juan ^a   Pineda, Juan A ^a  

^a HOSPITAL UNIVERSITARIO DE VALME   (Spain)

^b HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

^c Maimonides Institute for Research in Biomedicine of Cordoba   (Spain)

^d HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

^e HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^f HOSPITAL UNIVERSITARIO PUERTA DEL MAR   (Spain)

^g HOSPITAL UNIVERSITARIO VIRGEN DE LA VICTORIA   (Spain)

^h HOSPITAL JUAN RAMÓN JIMÉNEZ   (Spain)

ⁱ Unidad de Enfermedades Infecciosas   (Spain)

^j HOSPITAL UNIVERSITARIO VIRGEN MACARENA   (Spain)

^k Unidad de Enfermedades Infecciosas   (Spain)

more..

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 28B; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN; VIRUS RNA;

ADULT; ARTICLE; DRUG EFFICACY; DRUG WITHDRAWAL; FEMALE; GENE; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IL28B GENE; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; MULTICENTER STUDY; NONHUMAN; PATIENT COMPLIANCE; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

ANTIVIRAL AGENTS; COINFECTION; DRUG THERAPY, COMBINATION; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C; HIV INFECTIONS; HUMANS; INTERFERON-ALPHA; MALE; POLYETHYLENE GLYCOLS; RECOMBINANT PROTEINS; RIBAVIRIN; TREATMENT OUTCOME;

EID: 84865486566     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e3283568884     Document Type: Article

References (8)

1. Martín-Carbonero L, Puoti M, García-Samaniego J, De Luca A, Losada E, Quinzan G, et al. Response to pegylated interferon plus ribavirin in HIV-infected patients with chronic hepatitis C due to genotype 4. J Viral Hept 2008; 15:710-715.
2. Khattab MA, Ferenci P, Hadziyannis SJ, Colombo M, Manns MP, Almasio PL, et al. Management of hepatitis C virus genotype 4: recommendations of an international expert panel. J Hepatol 2011; 54:1250-1262.
3. Recommendations of Gesida/PNS/AEEH for the management and treatment of the adult patient co-infected with HIV and hepatitis A, B and C virus. EnfermInfeccMicrobiolClin 2010; 28:1-31.
4. European AIDS Clinical Society (EACS). Guidelines for the clinical management and treatment of chronic hepatitis B and C coinfection in HIV-infected adults. http://www.europeanaid sclinicalsociety.org/guidelines.asp. [Accessed 10 March 2011]
5. Torriani FJ, Rodríguez-Torres M, Rockstroh JK, Lissen E, González-García J, Lazzarin A, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med 2004; 351:438-450. (Pubitemid 38988593)
6. Carrat F, Bani-Sadr F, Pol S, Rosenthal E, Lunel-Fabiani F, Benzekri A, et al. Pegylated interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients. A randomized controlled trial. JAMA 2004; 292:2839-2848. (Pubitemid 39628231)
7. Pineda JA, Mira JA, de los Santos-Gil I, Valera-Bestard B, Rivero A, Merino D, et al. Influence of concomitant antiretroviral therapy on the rate of sustained virological response to pegylated interferon plus ribavirin in hepatitis C virus/HIV-coinfected patients. J Antimicrob Chemother 2007; 60:1347-1354. (Pubitemid 350168332)
8. Roulot D, Bourcier V, Grando V, Deny P, Baazia Y, Fontaine H, et al. , Observational VHC4 Study Group. Epidemiological characteristics and response to peginterferon plus ribavirin treatment of hepatitis C virus genotype 4 infection. J Viral Hepat 2007; 14:460-467. (Pubitemid 46944469)